c-Jun N-Terminal Kinase Pathway Activation in Human and Experimental Cerebral Contusion
- 1 September 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Neuropathology & Experimental Neurology
- Vol. 68 (9) , 964-971
Abstract
The c- Jun N-terminal kinase (JNK) pathway is involved in cell stress and apoptosis. We tested the hypothesis that this pathway plays a role in traumatic brain injury (TBI) by assessing JNK activation in human brain tissues and in brains of mice subjected to controlled cortical impact brain injury. We also assessed the effects of specific inhibition of the JNK pathway by the cell-permeable JNK inhibitor peptide, D-JNKI1, on neurobehavioral function and posttraumatic cellloss in mice. The inhibitor was administered intraperitoneally 10minutes after injury. The JNK pathway showed robust activation both in human contusion specimens and in injured cortex and hippocampi of TBI-injured mice, 1, 4, and 48 hours after injury. D-JNKI1 treatment significantly improved motor performance at 48 hours and 7days after injury and reduced the contusion volume compared withsaline treatment; the numbers of terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive cells were significantly decreased in the hippocampi of injured mice 48 hours after treatment. Thus, because the JNK pathway is activated after human and experimental TBI and the inhibitor peptide D-JNKI1 affords significant neuroprotection and amelioration of neurobehavioral deficits after experimental TBI, therapeutic targeting of the JNK activation pathway may hold promise for future clinical applications.Keywords
This publication has 43 references indexed in Scilit:
- C1-inhibitor attenuates neurobehavioral deficits and reduces contusion volume after controlled cortical impact brain injury in mice*Critical Care Medicine, 2009
- Classification of Traumatic Brain Injury for Targeted TherapiesJournal of Neurotrauma, 2008
- Neurotrophin receptors expression and JNK pathway activation in human astrocytomasBMC Cancer, 2007
- Novel Strategy for Treatment of Viral Central Nervous System Infection by Using a Cell-Permeating Inhibitor of c-Jun N-Terminal KinaseJournal of Virology, 2007
- A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemia-reperfusion injury and infarct size in vivoAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- Uses for JNK: the Many and Varied Substrates of the c-Jun N-Terminal KinasesMicrobiology and Molecular Biology Reviews, 2006
- Role of the JNK pathway in NMDA-mediated excitotoxicity of cortical neuronsCell Death & Differentiation, 2006
- Ex Vivo Gene Therapy Using Targeted Engraftment of NGF-Expressing Human NT2N Neurons Attenuates Cognitive Deficits Following Traumatic Brain Injury in MiceJournal of Neurotrauma, 2004
- D-JNKI1, a Cell-Penetrating c-Jun-N-Terminal Kinase Inhibitor, Protects Against Cell Death in Severe Cerebral IschemiaStroke, 2004
- Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.Journal of Cell Biology, 1992